Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2021 Jan 19;76(2):482-486.
doi: 10.1093/jac/dkaa441.

Safety of hydroxychloroquine and darunavir or lopinavir in COVID-19 infection

Etienne Meriglier  1   2 , Claire Rivoisy  1 , Mojgan Hessamfar  1 , Noelle Bernard  1 , Ines Aureau  1 , Joelle Lapoirie  1   2 , Anne Contis  1 , Frédéric Sacher  2   3 , Benjamin Sacristan  2 , Marin Lahouati  4 , Stéphane Pedeboscq  4 , Marie-Anne Vandenhende  1   2 , Stéphane Bouchet  5 , Fabrice Bonnet  1   2
Affiliations
Observational Study

Safety of hydroxychloroquine and darunavir or lopinavir in COVID-19 infection

Etienne Meriglier et al. J Antimicrob Chemother. .

Abstract

Background: Combination therapy with hydroxychloroquine and darunavir/ritonavir or lopinavir/ritonavir has been suggested as an approach to improve the outcome of patients with moderate/severe COVID-19 infection.

Objectives: To examine the safety of combination therapy with hydroxychloroquine and darunavir/ritonavir or lopinavir/ritonavir.

Methods: This was an observational cohort study of patients hospitalized for COVID-19 pneumonia treated with hydroxychloroquine and darunavir/ritonavir or lopinavir/ritonavir. Clinical evaluations, electrocardiograms and the pharmacokinetics of hydroxychloroquine, darunavir and lopinavir were examined according to clinical practice and guidelines.

Results: Twenty-one patients received hydroxychloroquine with lopinavir/ritonavir (median age 68 years; 10 males) and 25 received hydroxychloroquine with darunavir/ritonavir (median age 71 years; 15 males). During treatment, eight patients (17.4%) developed ECG abnormalities. Ten patients discontinued treatment, including seven for ECG abnormalities a median of 5 (range 2-6) days after starting treatment. All ECG abnormalities reversed 1-2 days after interrupting treatment. Four patients died within 14 days. ECG abnormalities were significantly associated with age over 70 years, coexisting conditions (such as hypertension, chronic cardiovascular disease and kidney failure) and initial potential drug interactions, but not with the hydroxychloroquine concentration.

Conclusions: Of the patients with COVID-19 who received hydroxychloroquine with lopinavir or darunavir, 17% had ECG abnormalities, mainly related to age or in those with a history of cardiovascular disease.

PubMed Disclaimer

References

    1. Yao X, Ye F, Zhang M. et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020; 71: 732–9. - PMC - PubMed
    1. Wang M, Cao R, Zhang L. et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30: 269–71. - PMC - PubMed
    1. Kim AHJ, Sparks JA, Liew JW. et al. A rush to judgment? Rapid reporting and dissemination of results and its consequences regarding the use of hydroxychloroquine for COVID-19. Ann Intern Med 2020; 172: 819–21. - PMC - PubMed
    1. Rosenberg ES, Dufort EM, Udo T. et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. JAMA 2020; 323: 2493–502. - PMC - PubMed
    1. Tang W, Cao Z, Han M. et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ 2020; 369: m1849. - PMC - PubMed

Publication types

MeSH terms